Washington, DC (March 14, 2014)
Patrick Conway, M.D., Deputy Administrator for Innovation and Quality and Chief Medical Officer, Centers for Medicare & Medicaid Services (CMS), delivered the keynote address at the Tenth Annual State of Personalized Medicine Luncheon hosted by the Personalized Medicine Coalition (PMC) at the National Press Club.
"As our understanding of individual variation continues to develop, personalized medicine products must overcome three challenges before patients can benefit," said Edward Abrahams, President of PMC. “In the United States, they must pass regulatory muster at either CMS or FDA, be covered and paid for, and be adopted by practicing clinicians. We are delighted Dr. Conway was able to provide his critical perspective on that second challenge in a discussion of sustaining innovation in an era of health care reform.”
Attended by 200 innovators, patients, scientists, and government officials devoted to the understanding and improvement of health care, Dr. Conway outlined his perspective on the state of personalized medicine and where it is headed.
“Innovation is happening broadly across the country. The promise of personalized medicine and innovation is amazing, and we’re already seeing dividends,” Dr. Conway stated in his address.
Pat Balthrop, CEO of Luminex Corporation, the sponsor of this year’s event, introduced Dr. Conway.
The Personalized Medicine Coalition's annual "State of Personalized Medicine Luncheon" serves as a forum for PMC members and guests from across the health care community to engage policy leaders in a discussion of the key issues facing personalized medicine. Dr. Conway’s presentation is available here.
Previous keynote speakers at the State of Personalized Medicine Luncheon have included Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research of the Food and Drug Administration (FDA); Mark Levin, Partner and Co-Founder of Third Rock Ventures; John Castellani, President and CEO of PhRMA; Margaret Hamburg, M.D., Commissioner of FDA; Denis Cortese, M.D., President and CEO of the Mayo Clinic; Harvey Fineberg, M.D., President of the Institute of Medicine; The Honorable Michael O. Leavitt, Secretary of Health and Human Services; Andrew von Eschenbach, M.D., Commissioner of FDA; and Francis Collins, M.D., Ph.D., Director of the National Human Genome Research Institute.
About the Personalized Medicine Coalition:
The Personalized Medicine Coalition (PMC), representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. For more information about PMC, visit www.personalizedmedicinecoalition.org.